IPO周报 | 宁德时代、恒瑞医药港股上市在即；圣贝拉获上市备案通知书

Core Viewpoint - The article discusses the upcoming IPOs of several companies, including CATL and Hengrui Medicine, highlighting their financial performance, market positioning, and investor interest. Group 1: CATL - CATL plans to list on the Hong Kong Stock Exchange on May 20, 2025, with the stock code "3570" [3] - The company aims to issue 117,894,500 H-shares, raising approximately HKD 30.718 billion (around USD 3.941 billion) at an issue price of HKD 263 per share [3] - This IPO will be the largest in Hong Kong since Kuaishou in 2021, with cornerstone investors committing a total of USD 2.628 billion [4] - As of December 31, 2024, CATL has equipped over 17 million electric vehicles with its batteries, capturing a significant market share [4] - The company has established partnerships with nine of the top ten global electric vehicle manufacturers and has seen revenue growth from CNY 328.6 billion in 2022 to CNY 362 billion in 2024 [5] Group 2: Hengrui Medicine - Hengrui Medicine is set to go public on May 23, 2025, under the stock code "1276" [7] - The company plans to issue 224,519,800 H-shares, potentially raising up to HKD 9.89 billion (approximately USD 1.267 billion) at a top-end price of HKD 44.05 per share [7] - Hengrui has attracted cornerstone investments totaling USD 533 million from major institutions, including GIC and Invesco [7] - The company has a diverse product portfolio, with 19 innovative drugs already on the market and over 90 in clinical or later stages [8] - Hengrui's revenue has grown from CNY 21.275 billion in 2022 to CNY 27.985 billion in 2024, with a compound annual growth rate of 14% since 2014 [10] Group 3: Mirxes - Mirxes has passed the hearing for its IPO and focuses on miRNA technology for disease screening solutions [13] - The company has commercialized its core product, GASTROClear™, for gastric cancer screening and has additional products in various stages of development [13][14] Group 4: Shouhui Group - Shouhui Group has also passed the hearing for its IPO and operates as an online insurance intermediary in China [16] - The company has established partnerships with over 110 insurance companies and has distributed more than 1,900 products since its inception [17] - Financially, Shouhui's revenue increased from CNY 806 million in 2022 to CNY 1.634 billion in 2023 [18] Group 5: Saint Bella - Saint Bella has received a notice for its overseas listing and operates a network of high-end confinement centers in China [19] - The company has expanded its services to include family care and women's health products, achieving significant revenue growth [20][21] - From 2021 to 2023, Saint Bella's revenue grew from CNY 259 million to CNY 560 million, with a notable increase in 2024 [21][22]